Baxter (BAX) Insider Report: 3,191 Shares Forfeited for Taxes
Rhea-AI Filing Summary
Alok Sonig, EVP & Group President, Pharma at Baxter International (BAX), reported a transaction on 09/02/2025. He relinquished 3,191 shares of Baxter common stock at a price of $24.17 per share to cover tax withholding tied to the delivery of vested restricted stock units granted on 09/01/2022. After the transaction, the reporting person beneficially owns 128,219 shares, which the filing notes includes automatic dividend reinvestment. The sale was reported on a Form 4 signed by an attorney-in-fact on 09/04/2025.
Positive
- Continued significant ownership: Reporting person still beneficially owns 128,219 shares after the transaction
- Transaction clearly explained: Filing specifies the shares were forfeited to cover tax withholding from vested RSUs granted on 09/01/2022
Negative
- Shares disposed: 3,191 shares were surrendered on 09/02/2025
- Sale price disclosed: Shares covered withholding at $24.17 per share, indicating a realized reduction in holding
Insights
TL;DR: Routine tax-withholding disposition of vested RSUs; continues to hold substantial shares.
The Form 4 documents a standard tax-withholding sale following RSU delivery rather than a voluntary open-market divestiture. The report identifies the grant date of the RSUs (09/01/2022) and explains that 3,191 shares were forfeited to cover withholding obligations, leaving 128,219 shares beneficially owned. This is a common administrative transaction and does not indicate a change in control or a strategic shift by management.
TL;DR: Small-scale disposition at $24.17/share tied to compensation vesting; minimal investor impact.
The disposal was executed at $24.17 per share on 09/02/2025 and is explicitly for tax withholding resulting from vested restricted stock units. The filing discloses continued beneficial ownership of 128,219 shares, including reinvested dividends. Given the transaction size relative to typical insider holdings and the stated purpose, this should be considered routine and unlikely to materially affect investor valuation.